Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
42
NKTR Quote, Financials, Valuation and Earnings
Last price:
$44.43
Seasonality move
:
6.44%
Day range:
$42.95 - $44.55
52-week range:
$6.48 - $66.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.83x
P/B ratio:
8.84x
Volume:
1.5M
Avg. volume:
878.7K
1-year change:
229.15%
Market cap:
$752.2M
Revenue:
$98.4M
EPS (TTM):
-$4.56
Analysts' Opinion
-
Consensus RatingNektar Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $114.43, Nektar Therapeutics has an estimated upside of 163.18% from its current price of $44.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $102.00 representing 100% downside risk from its current price of $44.46.
Fair Value
-
According to the consensus of 7 analysts, Nektar Therapeutics has 163.18% upside to fair value with a price target of $114.43 per share.
NKTR vs. S&P 500
-
Over the past 5 trading days, Nektar Therapeutics has underperformed the S&P 500 by -20.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nektar Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nektar Therapeutics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Nektar Therapeutics reported revenues of $11.8M.
Earnings Growth
-
Nektar Therapeutics earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Nektar Therapeutics reported earnings per share of -$1.87.
Enterprise value:
649.1M
EV / Invested capital:
2.57x
Price / LTM sales:
44.83x
EV / EBIT:
--
EV / Revenue:
10.37x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-3.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$53.8M
Return On Assets:
-43.84%
Net Income Margin (TTM):
-192.87%
Return On Equity:
-327.67%
Return On Invested Capital:
-54.14%
Operating Margin:
-267.45%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $88.3M | $93.1M | $62.6M | $24.1M | $11.8M | |
| Gross Profit | $55.5M | $63.1M | $53.8M | $19.7M | $11.6M | |
| Operating Income | -$145.5M | -$135.9M | -$136.4M | -$34.3M | -$31.5M | |
| EBITDA | -$136.9M | -$130.2M | -$135.2M | -$33.3M | -$31.3M | |
| Diluted EPS | -$1.55 | -$0.84 | -$4.56 | -$0.18 | -$1.87 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $986.1M | $599.5M | $399M | $286.5M | $281.4M | |
| Total Assets | $1.3B | $781M | $442.2M | $308M | $301.3M | |
| Current Liabilities | $140M | $84M | $52.1M | $67.6M | $66.3M | |
| Total Liabilities | $475.7M | $368.8M | $282.9M | $259.1M | $216.3M | |
| Total Equity | $801.5M | $412.2M | $159.4M | $48.9M | $85.1M | |
| Total Debt | $310.5M | $281.7M | $225.8M | $184.6M | $144.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$203.3M | -$176.6M | -$189.7M | -$43.9M | -$48.8M | |
| Cash From Investing | $162.2M | $99.7M | $58.6M | $46.1M | -$94.9M | |
| Cash From Financing | $121K | $42M | $142M | $13K | $141.7M | |
| Free Cash Flow | -$204.4M | -$177.8M | -$190.4M | -$44.6M | -$48.9M | |
NKTR
Sector
Market Cap
$752.2M
$28.4M
Price % of 52-Week High
64.97%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-13.36%
-1.49%
1-Year Price Total Return
212.26%
-16.67%
Beta (5-Year)
1.268
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$47.67
200-day SMA
Buy
Level
$31.84
Bollinger Bands (100)
Sell
Level
35.93 - 62.65
Chaikin Money Flow
Buy
Level
14.2M
20-day SMA
Sell
Level
$54.26
Relative Strength Index (RSI14)
Sell
Level
37.11
ADX Line
Sell
Level
26.56
Williams %R
Buy
Level
-94.8224
50-day SMA
Sell
Level
$56.89
MACD (12, 26)
Sell
Level
-3.56
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
66.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.4756)
Sell
CA Score
(Annual)
Level (-3.107)
Buy
Beneish M-Score
(Annual)
Level (-2.4653)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.3897)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, NKTR has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NKTR average analyst price target in the past 3 months is $114.43.
-
Where Will Nektar Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nektar Therapeutics share price will rise to $114.43 per share over the next 12 months.
-
What Do Analysts Say About Nektar Therapeutics?
Analysts are divided on their view about Nektar Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nektar Therapeutics is a Sell and believe this share price will drop from its current level to $102.00.
-
What Is Nektar Therapeutics's Price Target?
The price target for Nektar Therapeutics over the next 1-year time period is forecast to be $114.43 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NKTR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nektar Therapeutics is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NKTR?
You can purchase shares of Nektar Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nektar Therapeutics shares.
-
What Is The Nektar Therapeutics Share Price Today?
Nektar Therapeutics was last trading at $44.43 per share. This represents the most recent stock quote for Nektar Therapeutics. Yesterday, Nektar Therapeutics closed at $44.46 per share.
-
How To Buy Nektar Therapeutics Stock Online?
In order to purchase Nektar Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NKTR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NKTR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
8.84x
1.81x
Price / LTM sales
44.83x
1.58x
Growth Metrics
NKTR
Sector
Revenue growth
-51.13%
4.62%
Earnings growth
-958.61%
10.7%
Revenue (5-year growth)
-3%
6.5%
Earnings forecast
-$2.79
-$0.21
Profitability
NKTR
Sector
Profitability FY 2024
$66.5M
$3.6M
Return on invested capital
-54.14%
-31.84%
Return on assets
-43.84%
-27.96%
Return on equity
-327.67%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
5
Balance Sheet
NKTR
Sector
Total cash
$270.2M
$26.4M
Short term investments
$211M
$25.7M
Total assets
$303.9M
$76.9M
Long term debt
$144.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
